Enliven Therapeutics, Inc. Share Price & Technical Analysis
ELVN · $41.54 (-1.68%)
Healthcare / Biotechnology
$41.54
-1.68%
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
0% return in May, 6% avg return in past 3 year May month.
126% return in 2026, 9% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 71% | 13% | 36% | 5% | 0% | – | – | – | – | – | – | – | 126% |
| 25 | -4% | -2% | -5% | -3% | -6% | 13% | -6% | 10% | 1% | 15% | -7% | -28% | -22% |
| 24 | 13% | 2% | 9% | -1% | 28% | 1% | 13% | -17% | 18% | 9% | -13% | -8% | 52% |
| 23 | 12% | 17% | 3% | -12% | -4% | 10% | -7% | -17% | -12% | -9% | -7% | 24% | -2% |
| 22 | -38% | 11% | 23% | -27% | -11% | 7% | -2% | 2% | 98% | 93% | -5% | -1% | 149% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Uptrend · Uptrend
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.54B
P/E ratio
—
52W high
$48.53
52W low
$14.79
Volume
6,32,207
Beta
0.45
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Enliven Therapeutics, Inc. share price today?
- Enliven Therapeutics, Inc. (ELVN) last traded around $41.54 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ELVN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ELVN. Download the app for real-time alerts.
- How can I analyze Enliven Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.